메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Lee, Suk Hyun (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) Han, Sangwon (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) Lee, Hyo Sang (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) Chae, Sun Young (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) Lee, Jong Jin (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) Song, Dong Eun (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) Ryu, Jin-Sook (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine)
저널정보
대한핵의학회 Nuclear medicine and molecular imaging : NMMI Nuclear medicine and molecular imaging : NMMI 제50권 제1호
발행연도
2016.1
수록면
38 - 45 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence $^{18}F$-fluoro-2-deoxyglucose> ($^{18}F$-FDG) avidity. Methods We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and $^{18}F$-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be $^{18}F$-FDG avid if the uptake was greater than that of the liver. $^{18}F$-FDG uptake of PTCs was also analyzed semiquantitatively using $SUV_{max}$. The association between $^{18}F$-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated. Results Twenty-nine (52.7 %) of 55 patients had $^{18}F$-FDG-avid PTCs. PTCs with the BRAF mutation showed higher $^{18}F$-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p=0.025) and tumor size (p=0.003) were significantly associated with $^{18}F$-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p=0.015). In the subgroup of tumor $size{\geq}1cm$, the BRAF mutation was the only factor significantly associated with $^{18}F$-FDG avidity (p=0.021). The mean $SUV_{max}$ of PTCs with the BRAF mutation was significantly higher than that of those without ($4.89{\pm}6.12$ vs. $1.96{\pm}1.10$, p=0.039). Conclusions The BRAF mutation must be one of the most important factors influencing $^{18}F$-FDG avidity in PTCs, especially in those with a tumor $size{\geq}1cm$.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0